COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA
Author(s): ,
Arantxa Carrasco-Leon
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Teresa Ezponda
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Cem Meydan
Affiliations:
Hematology/Oncology,Weill Cornell Medical College,New York,United States
,
Luis Vítores Valcárcel
Affiliations:
Tecnun School of Engineering,University of Navarra,San Sebastián,Spain
,
Raquel Ordoñez
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Marta Kulis
Affiliations:
Fundamentos Clínicos,Universitat de Barcelona,Barcelona,Spain
,
Leire Garate
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Estibaliz Miranda
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Víctor Segura
Affiliations:
Bioinformatics,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Elisabeth Guruceaga
Affiliations:
Bioinformatics,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Amaia Vilas-Zornoza
Affiliations:
Hematology/Oncology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Diego Alignani
Affiliations:
Flow Citometry Core,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Laura Castro-Labrador
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Marién Pascual
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),New York,Spain
,
Ane Amundarain
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
,
Halima El-Omri
Affiliations:
Hamad Medical Corporation,Doha,Qatar
,
Ruba Y Taha
Affiliations:
Hamad Medical Corporation,Doha,Qatar
,
María J. Calasanz
Affiliations:
CIMA Lab Diagnostics,Weill Cornell Medical College,Pamplona,Spain
,
Francisco J. Planes
Affiliations:
Computational Biomedicine,Weill Cornell Medical College,New York,United States
,
Christopher Mason
Affiliations:
Hematology/Oncology,Weill Cornell Medical College,New York,Spain
,
Jesús San Miguel
Affiliations:
Hematology,Clinica Universidad de Navarra,Pamplona,Spain
,
José I. Martin Subero
Affiliations:
Fundamentos Clínicos,Universitat de Barcelona,Barcelona,Spain
,
Ari Melnick
Affiliations:
Hematology/Oncology,Weill Cornell Medical College,New York,United States
,
Felipe Prosper
Affiliations:
Hematology,Clinica Universidad de Navarra,Pamplona,Spain
Xabier Agirre
Affiliations:
Onco-hematology,Center for Applied Medical Research (CIMA),Pamplona,Spain
EHA Library. Carrasco A. Jun 14, 2019; 266382; PF583
Arantxa Carrasco
Arantxa Carrasco
Contributions
Abstract

Abstract: PF583

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background
Deregulation of long non-coding RNAs (lncRNAs) is emerging as a common hallmark of different human tumors and their investigation may uncover novel biomarkers and oncogenic mechanisms. In multiple myeloma (MM), the alteration of some lncRNAs has been detected, suggesting that they can play an important role, but the complete transcriptome of the lncRNAs in this disease is not yet known.

Aims
In the present work, our objective was to characterize the complete transcriptome of the lncRNAs in the MM, to determine their functional involvement in the myelomagenesis and in the clinical outcome of the patients.

Methods
We performed the paired-end strand-specific RNA sequencing (ssRNA-seq) in 38 purified plasma cell (PC) samples from MM patients and in 3 bone marrow PCs (BMPCs) of healthy donors. We also performed the same ssRNA-seq in distinct B cell subpopulations (Naïve, Cetroblast, Centrocyte, Memory and Tonsilar PCs). To study the heterogeneity of lncRNAs expression, we compared each MM patient with BMPCs and studied their expression dynamism along human humoral immune response and MM patients. We also determined the epigenetic deregulation of those dynamic lncRNAs by analyzing the chromatin states of their promoter regions. The functional implication of one lncRNA, LINC-SMILO (Specific Myeloma INtergenic LOng non-coding RNA), was analyzed in MM cell lines by its knockdown using shRNAs, analyzing the cell phenotype using MTS (cell proliferation) and annexin V (death) assays. Finally, using the data from CoMMpass, we studied the biomarker potential of lncRNAs expressed specifically in MM through analyzing the overall survival of MM patients.

Results
We identified 40.511 novel lncRNAs that were expressed in MM patients, showing a much more heterogeneous expression than the coding genes. After the comparative analysis between each MM patient and BMPCs, we detected 16.668 lncRNAs deregulated (11,067 were overexpressed and 5,601 downregulated) in more than 40% of patients. Analysis of the transcriptional dynamisms through the distinct B cell subpopulations showed 1.465 lncRNAs exclusive expression in MM, from which 31 showed de novo epigenomic activation. To determine the functional role of such altered lncRNAs in the biology of MM cells we focused on the study of LINC-SMILO, epigenetically de novo activated and specifically expressed in MM cells. Knockdown of LINC-SMILO in 3 different MM cell lines (MM.1S, MM.1R and KMS-11) resulted in reduced proliferation and induction of apoptosis by activation of ERVs and modulation of IFN pathway, indicating that this lncRNA is essential for the survival of MM cells. Finally, we showed that overexpression of the lncRNA PDLIM1P4 together with amp1q and del17p genetic alterations, divides MM patients in three prognostic risk groups.

Conclusion
In summary, our study shows the complexity of the lncRNA transcriptome in MM, and suggests that some of these lncRNAs may be a potential prognostic markers or key therapeutic targets for the treatment of this disease.

Session topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research

Keyword(s): Epigenetic, Myeloma

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies